What Is Eli Lilly Stock's Biggest Opportunity?

Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. Justifying that multiple may require sustained growth, yet most of Lilly's sales still come from the company's two dominant blockbusters, Zepbound and Mounjaro. The pharmaceutical maker has a newer drug on sale and expects to launch it in all major markets worldwide in 2027. So what is the new drug, and is it selling.